Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Ras is mutated in many cancers, but so far no drug targeting Ras is in clinical use despite great efforts. Here the authors structurally and functionally characterize a DARPin that potently inhibits the nucleotide exchange of Ras, which might facilitate the development of Ras-targeted therapies.
Guardado en:
Autores principales: | Sandrine Guillard, Paulina Kolasinska-Zwierz, Judit Debreczeni, Jason Breed, Jing Zhang, Nicolas Bery, Rose Marwood, Jon Tart, Ross Overman, Pawel Stocki, Bina Mistry, Christopher Phillips, Terence Rabbitts, Ronald Jackson, Ralph Minter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/511b9c0f118d47a5b8dc1ab52f044f6e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
por: Nicolas Bery, et al.
Publicado: (2019) -
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
por: Tomoyuki Tanaka, et al.
Publicado: (2021) -
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Camilo E. Quevedo, et al.
Publicado: (2018) -
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020) -
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from <named-content content-type="genus-species">Clostridium difficile</named-content> Ribotype 027
por: Zeyu Peng, et al.
Publicado: (2019)